AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1323974 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon beta serine
Number of subjects: 38
Study 1323974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 6721016 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health aides offered to patients
Number of subjects: 227
Study 6721016 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aides)
Number of subjects: 227
Study 6721016 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health aides accepted by 44 patients
Number of subjects: 227
Study 31847912 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) testing
Number of subjects: 2940
Study 31847912 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced communication skills with patient leaflets
Number of subjects: 2940
Study 31847912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions (CRP testing + enhanced communication skills)
Number of subjects: 2940
Study 31847912 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2940
Study 29775959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with 15.8 mg/g nicotine
Number of subjects: 50
Study 29775959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with 5.2 mg/g nicotine
Number of subjects: 50
Study 29775959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with 1.3 mg/g nicotine
Number of subjects: 50
Study 29775959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.4 mg/g nicotine
Number of subjects: 50
Study 27434595 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium-89 (Sr-89) with docetaxel
Number of subjects: 757
Study 27434595 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) with docetaxel
Number of subjects: 757
Study 27434595 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic Zoledronic acid (ZA) with docetaxel
Number of subjects: 757
Study 27434595 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary Zoledronic acid (ZA) with docetaxel
Number of subjects: 757
Study 27434595 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 757
Study 24464687 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Ejection Fraction (LVEF < 40%)
Number of subjects: 7007
Study 24464687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate Ejection Fraction (LVEF 40-50%)
Number of subjects: 7007
Study 24464687 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved Ejection Fraction (LVEF > 50%)
Number of subjects: 7007
Study 24464687 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF as a continuous variable
Number of subjects: 7007
Study 24464687 — intervention group
Group type: COMPARATOR
Intervention: Multivariable adjustment for LowEF
Number of subjects: 7007
Study 24464687 — intervention group
Group type: COMPARATOR
Intervention: Multivariable adjustment for IntEF
Number of subjects: 7007
Study 22824768 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation and anti-H. pylori therapy (Group I)
Number of subjects: 20
Study 22824768 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation only (Group II)
Number of subjects: 20
Study 22824768 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 20
Study 18330516 — intervention group
Group type: EXPERIMENTAL
Intervention: Full perfusion (APS 10-12)
Number of subjects: 168
Study 17804905 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 627
Study 17804905 — intervention group
Group type: COMPARATOR
Intervention: Aspirin therapy
Number of subjects: 627
Study 15248226 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg subcutaneously twice weekly for 24 weeks
Number of subjects: 205
Study 15248226 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 205
Study 15248226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 11755921 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 292
Study 11755921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 9659650 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (100 micrograms intravenous injection)
Number of subjects: 57
Study 9659650 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (continuous 16 hour infusion)
Number of subjects: 57
Study 7806654 — intervention group
Group type: EXPERIMENTAL
Intervention: Role playing scenarios
Number of subjects: 0
Study 2534405 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) at 0.005 microgram/kg per min
Number of subjects: 7
Study 2534405 — intervention group
Group type: EXPERIMENTAL
Intervention: D-sulpiride at 0.05 mg/kg per min
Number of subjects: 7
Study 2534405 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) + D-sulpiride at the same doses
Number of subjects: 7
Study 2534405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline for 60 min)
Number of subjects: 7
Study 786773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide (M)
Number of subjects: 20
Study 786773 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 20
Study 30898819 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal neuronavigation-guided precision bypass
Number of subjects: 100
Study 30898819 — intervention group
Group type: COMPARATOR
Intervention: Empirical bypass
Number of subjects: 100
Study 28646935 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic Urethral Lift (PUL) procedure
Number of subjects: 206
Study 28646935 — intervention group
Group type: COMPARATOR
Intervention: Blinded sham control
Number of subjects: 206
Study 25126957 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg daily for 40 days)
Number of subjects: 44
Study 25126957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 21971959 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stage cervical and endometrial cancer treatment
Number of subjects: 53
Study 21971959 — intervention group
Group type: COMPARATOR
Intervention: Benign gynaecological conditions (n = 60)
Number of subjects: 53
Study 21971959 — intervention group
Group type: COMPARATOR
Intervention: Pre-invasive cancer patients (n = 52)
Number of subjects: 53
Study 21272198 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians with a higher percentage of patients with hypertension
Number of subjects: 0
Study 21272198 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians with a higher number of total clinic visits per day
Number of subjects: 0
Study 21272198 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians with inpatient duties
Number of subjects: 0
Study 19427219 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of 0.33 Hz
Number of subjects: 15
Study 19427219 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of 0.66 Hz
Number of subjects: 15
Study 19427219 — intervention group
Group type: COMPARATOR
Intervention: Frequency of 0.33 Hz and 0.66 Hz
Number of subjects: 15
Study 16990976 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (20 IU injection)
Number of subjects: 30
Study 16990976 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl trinitrate ointment (300 mg of 0.2% applied three times daily for 30 days)
Number of subjects: 30
Study 12821497 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 0
Study 12821497 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of valacyclovir and cephalexin
Number of subjects: 0
Study 10848841 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma viscosity
Number of subjects: 964
Study 10848841 — intervention group
Group type: COMPARATOR
Intervention: Plasma viscosity (top quintile)
Number of subjects: 964
Study 8633687 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex, 750 mg/day for 2 days, then 1,000 mg/day on days 3-5, adjusted as clinically indicated for 21 days
Number of subjects: 65
Study 8633687 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex, serum levels >= 125 micrograms/ml
Number of subjects: 65
Study 1538042 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Trental) 400 milligram tablets three times daily
Number of subjects: 64
Study 1538042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 6234271 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin for 7 days
Number of subjects: 758
Study 6234271 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin for 3 days
Number of subjects: 758
Study 6234271 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 758
Study 6234271 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole for 7 days
Number of subjects: 758
Study 6234271 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 758
Study 6234271 — intervention group
Group type: COMPARATOR
Intervention: Citrated nalidixic acid for 3 days
Number of subjects: 758
Study 30130437 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult BVM with different grips (3 grips: 3 fingers, 2 fingers, 1 finger)
Number of subjects: 50
Study 30130437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric BVM with different grips (3 grips: 3 fingers, 2 fingers, 1 finger)
Number of subjects: 50
Study 30130437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric BVM
Number of subjects: 50
Study 30130437 — intervention group
Group type: COMPARATOR
Intervention: Pediatric BVM vs Adult BVM
Number of subjects: 50
Study 31337169 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved-needle blocking group (CB)
Number of subjects: 88
Study 31337169 — intervention group
Group type: COMPARATOR
Intervention: Straight-needle blocking group (SB)
Number of subjects: 88
Study 31337169 — intervention group
Group type: COMPARATOR
Intervention: Straight needle no-blocking group (SN)
Number of subjects: 88
Study 31337169 — intervention group
Group type: COMPARATOR
Intervention: Curved-needle no-blocking group (CN)
Number of subjects: 88
Study 29100704 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal pre-dilation (balloon to core laboratory-derived reference vessel diameter ratio ≥1:1)
Number of subjects: 2973
Study 29100704 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel size selection (reference vessel diameter ≥2.25 mm and ≤3.75 mm)
Number of subjects: 2973
Study 29100704 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dilation (with a noncompliant balloon at ≥18 atm and larger than the nominal scaffold diameter, but not by >0.5 mm larger)
Number of subjects: 2973
Study 29100704 — intervention group
Group type: EXPERIMENTAL
Intervention: BVS implantation in properly sized vessels
Number of subjects: 2973
Study 29100704 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive pre-dilation
Number of subjects: 2973
Study 29100704 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal post-dilation
Number of subjects: 2973
Study 26495054 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 43
Study 26495054 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 43
Study 23504617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 63
Study 23504617 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylaxis
Number of subjects: 63
Study 21881569 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (400 mg)
Number of subjects: 64
Study 18810239 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum urate levels (measured in mg/dl)
Number of subjects: 15183
Study 16410646 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy pregnancy
Number of subjects: 182
Study 16410646 — intervention group
Group type: COMPARATOR
Intervention: Gestational hypertension
Number of subjects: 182
Study 12627066 — intervention group
Group type: EXPERIMENTAL
Intervention: Maze III surgery combined with mitral valve surgery (n=25)
Number of subjects: 35
Study 12627066 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve surgery without Maze III (n=10)
Number of subjects: 35
Study 12627066 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 11777142 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive retention tape (Mefix)
Number of subjects: 30
Study 11777142 — intervention group
Group type: COMPARATOR
Intervention: Alginate (Kaltostat)
Number of subjects: 30
Study 9033440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol 20 mg nocte (B20)
Number of subjects: 84
Study 9033440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol 10 mg nocte (B10)
Number of subjects: 84
Study 9033440 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 3 mg t.i.d. (T)
Number of subjects: 84
Study 9033440 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (P)
Number of subjects: 84
Study 8509565 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan (100 mg once daily, n = 93)
Number of subjects: 193
Study 8509565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 100)
Number of subjects: 193
Study 3549837 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (loading: 27.5 mug/kg per 10 min, maintenance: 0.375 mug/kg per min)
Number of subjects: 189
Study 3549837 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (loading: 50 mug/kg per 10 min, maintenance: 0.50 mug/kg per min)
Number of subjects: 189
Study 3549837 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (loading: 75 mug/kg per 10 min, maintenance: 0.75 mug/kg per min)
Number of subjects: 189
Study 3549837 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (loading: 50 mug/kg per 10 min, maintenance: 0.25 mug/kg per min)
Number of subjects: 189
Study 3549837 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (all doses)
Number of subjects: 189
Study 3549837 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (high dose)
Number of subjects: 189
Study 31594294 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy device (mUV/VIS and infrared light)
Number of subjects: 0
Study 31594294 — intervention group
Group type: COMPARATOR
Intervention: Placebo device (no light emission)
Number of subjects: 0
Study 29188481 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 250
Study 29188481 — intervention group
Group type: COMPARATOR
Intervention: Control group (no case management intervention)
Number of subjects: 250
Study 26845539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonablative fractional erbium laser 1,340 nm
Number of subjects: 46
Study 26845539 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling
Number of subjects: 46
Study 23832756 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 181
Study 23832756 — intervention group
Group type: COMPARATOR
Intervention: No Training
Number of subjects: 181
Study 23449874 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Streptococcus salivarius strain M18
Number of subjects: 100
Study 23449874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 20678799 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intravitreal injections of 0.5 mg ranibizumab
Number of subjects: 30
Study 20678799 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 monthly injections followed by dosing as needed (PRN)
Number of subjects: 30
Study 18271973 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Number of subjects: 7
Study 16556673 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg IN buserelin every day (group C)
Number of subjects: 23
Study 16556673 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg IN buserelin twice a day (group D)
Number of subjects: 23
Study 16556673 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg IN buserelin three times a day (group E)
Number of subjects: 23
Study 16556673 — intervention group
Group type: COMPARATOR
Intervention: 10,000 IU hCG followed by vaginal administration of micronized progesterone (3x 200 mg/day) (group A)
Number of subjects: 23
Study 12672279 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU wafers
Number of subjects: 240
Study 12672279 — intervention group
Group type: COMPARATOR
Intervention: Placebo wafers
Number of subjects: 240
Study 10902992 — intervention group
Group type: EXPERIMENTAL
Intervention: E = 1171 kJ + 12 mg iron
Number of subjects: 55
Study 10902992 — intervention group
Group type: COMPARATOR
Intervention: S = 104 kJ
Number of subjects: 55
Study 10902992 — intervention group
Group type: COMPARATOR
Intervention: M = 12 mg iron + 209 kJ
Number of subjects: 55
Study 9365036 — intervention group
Group type: EXPERIMENTAL
Intervention: HGV RT‐PCR positive post-transplant in 8 of 11 fulminant patients
Number of subjects: 14
Study 9365036 — intervention group
Group type: COMPARATOR
Intervention: HGV RT‐PCR positive in 5 of 21 control liver transplant recipients
Number of subjects: 14
Study 8263313 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg venlafaxine
Number of subjects: 16
Study 8263313 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg venlafaxine
Number of subjects: 16
Study 8263313 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg venlafaxine
Number of subjects: 16
Study 8263313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3032828 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre supplement of 7.3 g per day
Number of subjects: 20
Study 3032828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31429603 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with asthma and diabetes (n=unknown)
Number of subjects: 2431
Study 31429603 — intervention group
Group type: COMPARATOR
Intervention: Patients with only diabetes (n=unknown)
Number of subjects: 2431
Study 31429603 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic and diabetic patients using budesonide (up to 825 mcg)
Number of subjects: 2431
Study 29753161 — intervention group
Group type: EXPERIMENTAL
Intervention: INSPIRE online program (immediate access)
Number of subjects: 451
Study 27022068 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin/cyclophosphamide-docetaxel (EC-Doc)
Number of subjects: 459
Study 27022068 — intervention group
Group type: COMPARATOR
Intervention: 5-fluoruracil/epirubicin/cyclophosphamide (FEC)
Number of subjects: 459
Study 27022068 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous genomic grade index (GGI)
Number of subjects: 459
Study 27022068 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical subtyping (IHC4)
Number of subjects: 459
Study 24654699 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco-trabeculectomy
Number of subjects: 60
Study 24654699 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification alone
Number of subjects: 60
Study 22350703 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg rectal diclofenac (reduced to 25 mg for patients weighing <50 kg)
Number of subjects: 104
Study 22350703 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline infusion without diclofenac)
Number of subjects: 104
Study 16023511 — intervention group
Group type: EXPERIMENTAL
Intervention: MIT therapy
Number of subjects: 748
Study 16023511 — intervention group
Group type: COMPARATOR
Intervention: No MIT therapy
Number of subjects: 748
Study 16023511 — intervention group
Group type: EXPERIMENTAL
Intervention: Prayer
Number of subjects: 748
Study 16023511 — intervention group
Group type: COMPARATOR
Intervention: No prayer
Number of subjects: 748
Study 12481892 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (AMI) 910 mg/m2 in 15 min infusion preceding MEL 200 mg/m2
Number of subjects: 10
Study 12481892 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AMI)
Number of subjects: 10
Study 9637805 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diazepam gel (0.2 to 0.5 mg/kg based on age)
Number of subjects: 125
Study 9637805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 9637805 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diazepam gel
Number of subjects: 125
Study 8620677 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 600mg every 6 hours for 13 days
Number of subjects: 12
Study 8620677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8620677 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton with digoxin
Number of subjects: 12
Study 8620677 — intervention group
Group type: COMPARATOR
Intervention: Placebo with digoxin
Number of subjects: 12
Study 2577474 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin-14
Number of subjects: 7
Study 334206 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.6 mg
Number of subjects: 0
Study 334206 — intervention group
Group type: COMPARATOR
Intervention: Morphine 15 mg
Number of subjects: 0
Study 31629348 — intervention group
Group type: EXPERIMENTAL
Intervention: CES-HGel (carbohydrate-electrolyte solution with sodium alginate and pectin)
Number of subjects: 9
Study 31629348 — intervention group
Group type: COMPARATOR
Intervention: CES-Std (standard carbohydrate-electrolyte solution)
Number of subjects: 9
Study 31629348 — intervention group
Group type: EXPERIMENTAL
Intervention: CES-HGel
Number of subjects: 9
Study 31629348 — intervention group
Group type: COMPARATOR
Intervention: CES-Std
Number of subjects: 9
Study 30222805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab plus deferred laser (0.5 mg)
Number of subjects: 0
Study 30222805 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone acetonide (FAc) 0.2 μg/day
Number of subjects: 0
Study 26525313 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 140
Study 26525313 — intervention group
Group type: COMPARATOR
Intervention: Usual care without bupivacaine
Number of subjects: 140
Study 25509435 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 47
Study 25509435 — intervention group
Group type: COMPARATOR
Intervention: Reduced spino-epidural anesthesia
Number of subjects: 47
Study 22990933 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN), n=20
Number of subjects: 35
Study 22990933 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (control), n=15
Number of subjects: 35